SC 13G: Rapport Therapeutics, Inc.

AI Summary

SC 13G filing by Rapport Therapeutics, Inc..

Risk Assessment

Risk Level: low

FAQ

Key Financial Figures

• $0.001 — Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securiti

Filing Documents

• s13g_093024-rapportthera.htm (SC 13G) — 49KB
• 0000904454-24-000538.txt ( ) — 51KB

(a)

ITEM 1(a) NAME OF ISSUER: Rapport Therapeutics, Inc.

(b)

ITEM 1(b) ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES: 1325 Boylston Street, Suite 401, Boston, MA 02215

(a)

ITEM 2(a) NAME OF PERSON FILING: This statement is being filed by Johnson & Johnson, a New Jersey corporation (“J&J”), and Johnson & Johnson Innovation-JJDC, Inc., a Delaware corporation (“JJDC”). JJDC is a wholly-owned subsidiary of J&J. The securities reported herein as being held by J&J and JJDC are directly beneficially owned by JJDC. J&J may be deemed to indirectly beneficially own the securities that are directly beneficially owned by JJDC. The Joint Filing Agreement between J&J and JJDC is attached hereto as Exhibit A.

(b)

ITEM 2(b) ADDRESS OF PRINCIPAL BUSINESS OFFICE: J&J: One Johnson & Johnson Plaza, New Brunswick, NJ 08933 JJDC: 410 George Street, New Brunswick, NJ 08901

(c)

ITEM 2(c) CITIZENSHIP: J&J: New Jersey JJDC: Delaware

(d)

ITEM 2(d) TITLE OF CLASS OF SECURITIES: Common Stock, $0.001 par value (“Common Stock”)

(e)

ITEM 2(e) CUSIP NUMBER: 75383L102 CUSIP No. 75383L102 Page 5 of 7 ITEM 3 Not applicable. ITEM 4 The information requested in this item is incorporated herein by reference to the cover pages to this Schedule 13G. Percentage ownership is based on 36,576,457 shares of Common Stock outstanding as of August 8, 2024, as reported in the Issuer’s Report on Form 10-Q for the period ended June 30, 2024 filed with the Securities and Exchange Commission on August 8, 2024. ITEM 5 Not applicable. ITEM 6 Not applicable. ITEM 7 IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT COMPANY: Not applicable. ITEM 8 IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP: Not applicable. ITEM 9 NOTICE OF DISSOLUTION OF GROUP: Not applicable. ITEM 10 CERTIFICATION: Not applicable. CUSIP No. 75383L102 Page 6 of 7 SIGNATURE After reasonable inquiry and to the best of their knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct. Dated: October 18, 2024 JOHNSON & JOHNSON By: /s/ Marc Larkins Name: Marc Larkins Title: Secretary JOHNSON & JOHNSON INNOVATION-JJDC, INC. By: /s/ Jill McManus Name: Jill McManus Title: Assistant Treasurer CUSIP No. 75383L102 Page 7 of 7 EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that the statement on Schedule 13G to which this Agreement is annexed as Exhibit A, and any amendments thereto, is and will be filed on behalf of each of them in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. Dated: October 18, 2024 JOHNSON & JOHNSON By: /s/ Marc Larkins Name: Marc Larkins Title: Secretary JO

View Full Filing

View this SC 13G filing on SEC EDGAR